【摘要】 早产儿动脉导管未闭(PDA)是临床早产儿的常见病症,应早期积极治疗。目前药物关闭仍是最有效、方便和经济的治疗方法。过去20多年,吲哚美辛一直是内科保守治疗的主要方法,其PDA关闭率为46%～89%,但吲哚美辛有效血药浓度安全范围较窄,且可导致肾功能障碍、颅内出血、坏死性小肠结肠炎和肠穿孔等严重不良反应,严重高胆红素血症患儿更是禁用吲哚美辛。近年国外采用布洛芬治疗早产儿PDA,取得较好疗效,关闭率为73.0%～95.5%,且对肾脏、脑及消化道血流动力学影响较少。本文简要综述布洛芬在早产儿PDA治疗中的应用。更多还原

【Abstract】 Patent ductus arteriosus(PDA) is a common disease among extremely premature neonates and the management of which has always been a challenge to the neonatologists.Prophylactic or early pre-symptomatic treatment has been advocated as the first-line approach,and drug induced closure is yet the most effective,inexpensive, and convenient method.During the last two decades,indomethacin was often given as conservative treatment,and its closure rate in PDA was approximately 46%～89%.However,indomethacin may increase the number of undesirable or harmful effects.Therefore,extend the risks of developing renal damage,intraventricular hemorrhage(IVH),necrotizing enterocolitis(NEC),and enterobrosis,etc.Recently,ibuprofen is rapidly emerging as a new promising drug for treatment of PDA in preterm infants with possibly less renal adverse reactions.It is used as standard therapy to close PDA,and it has less influence on the hemodynamics of kidneys,brain and gastrointestinal tract.This paper reviewed the use of ibuprofen in preterm infants with PDA.更多还原